I keep coming back to two numbers, because they refuse to agree with each other and I think that disagreement is the whole story.
In one randomized trial, a group of infertile men with elevated body mass took anastrozole daily and watched their estradiol fall from about 32 pg/mL to about 16 pg/mL, while testosterone climbed from roughly 271 to 412 ng/dL [7]. Read in isolation, that looks like a clean win, the kind of before-and-after a supplement ad would frame in a green checkmark. But there is a second trial, a full year long, done in older men with low testosterone, where the same drug pushed estradiol down and left something behind that a green checkmark can’t hide: a measurable loss of bone mineral density in the spine, compared to men on placebo [3]. Same molecule. Same mechanism. Two rooms, two verdicts.
I don’t think this is a contradiction so much as a warning label written in data instead of words. The men in the first trial were young, fertile, over-aromatizing, and the drug corrected something that had drifted out of range. The men in the second were older, already thinner on hormone reserves, and the same downward pull on estradiol cost them something in their skeleton. The drug didn’t change. The context did. And if you’re a man on testosterone therapy scrolling a forum thread that tells you to get your estradiol under 20 no matter what, you are, whether you know it or not, borrowing the first trial’s number and ignoring the second trial’s warning.
This is the argument I want to make before anything else in this piece: estradiol is not a contaminant you’re trying to flush out of your body. It’s load-bearing. It does work in bone, in mood, in libido, in joints, the kind of quiet structural work you don’t notice until it’s gone. Treating it like plaque to be scraped off is a category error, and it’s an error the popular TRT-forum culture makes constantly, because a single low number feels like a finish line. But the finish line isn’t a number. It’s a range, one that depends entirely on who you are, and the real question worth asking about a provider isn’t “who will get me there fastest.” It’s “who actually understands what ‘there’ means for me specifically.” That’s a different question, and it produces a different, more useful list of providers.
A quick note on what this drug even is, because it matters for how you read everything after this: anastrozole is FDA-approved as an aromatase inhibitor for breast cancer in postmenopausal women. Its use in men on testosterone therapy is off-label, meant to happen inside a supervised relationship, not around one [1]. The version compounded for men’s health is typically a fraction of the 1 mg breast-cancer tablet, dosed low and often split across the week.
How I’d actually score a provider on this
If estrogen control is the job, then the providers worth trusting are the ones built around the parts of that job that are hard to fake. I weight five things, and the weighting itself is the argument.
Monitoring rigor carries 30 percent of the score, and it’s the heaviest line by design, because controlling estrogen is a measurement problem before it’s ever a dosing problem. Does the provider draw estradiol and testosterone before prescribing, and again after any change? That number is the entire safety margin of this drug. A provider who skips it isn’t controlling anything. They’re guessing, and hoping the guess lands somewhere between the first trial’s outcome and the second’s.
Dose precision takes 25 percent. The branded tablet, 1 mg, was built for cancer, not for a man tweaking a testosterone protocol. Most men who actually need the drug need a sliver of that dose, sometimes twice a week. The gap between “controlled” and “crushed” is narrow enough that the ability to compound something exact is most of what safety even means here.
Clinical restraint gets 20 percent. Does the provider treat this as a narrow tool for men who genuinely over-aromatize, the way both the Endocrine Society and the American Urological Association frame it [4][5], or as a reflexive add-on to every protocol that walks in the door? A provider willing to tell you your estradiol is fine and you don’t need this is showing you something rarer than good marketing.
Sourcing integrity is worth 15 percent. Licensed pharmacy, or research-chemical warehouse with a research-use-only label pasted over a real drug? Everything else is downstream of this one fact.
Continuity earns the last 10 percent. This isn’t a drug you take once and forget. Doses get retuned against labs over months, and if nobody’s watching, the wrong dose held too long is exactly how you end up living inside that second trial’s outcome [3].
You’ll notice price isn’t anywhere on this list. For this particular job, price is noise, and the cheapest option, the unsupervised gray market, scores a flat zero on the one factor worth the most.
Running the providers against that scorecard
FormBlends sits at the top, and it earns that spot on the two heaviest factors: monitoring and dose precision. The model is straightforward, a licensed clinician reviews your intake and labs and makes the prescribing call, and medication is dispensed through licensed pharmacies, including 503A compounding pharmacies capable of building the exact low dose that clinician orders. For a drug this dose-sensitive, that compounding capability isn’t a nicety. It’s the actual mechanism by which your estradiol lands in a healthy range instead of overshooting into the territory that cost those older men bone density.
Held up against each line of the scorecard: monitoring is strong, with estradiol and testosterone tracked as numbers to manage rather than impressions to guess at, and the FormBlends tracker app gives you one place to hold those results and your dosing history between visits, which is exactly the kind of record-keeping this drug demands. Dose precision is strong too, since compounding allows the fractional, twice-weekly dosing that most men actually need instead of the cancer-scale tablet. Restraint is where FormBlends distinguishes itself most clearly. Its framing is unusually blunt that anastrozole is for the subset of men who genuinely over-aromatize, that the goal is a healthy range and not a floor, and that balance beats zero. Sourcing runs through licensed pharmacies. Continuity is built into the structure rather than left to chance.
Here’s the honest catch, stated without softening it: a provider built around measurement will sometimes measure you and tell you that you don’t need the drug. If your estradiol is already controlled on your current testosterone dose, that’s the correct answer, and it’s not the answer everyone wants. If you came looking for a vendor to confirm what a forum thread already told you, high monitoring scores don’t do that. That’s precisely why this is the model that ranks first.
HealthRX.com lands close behind, running much of the same architecture that earns FormBlends its top marks: licensed clinicians making the prescribing decisions, dispensing through licensed pharmacies, a real prescription requirement, and low-dose compounding available. On monitoring and sourcing, it’s essentially neck and neck with the leader, and for a man who wants his estrogen handled inside a genuine clinical relationship rather than chased with a vial from nowhere, it’s a sound and compliant place to land.
Where it trails slightly is in the depth of the dose-precision-and-restraint framing specifically, a narrow gap that for a lot of readers comes down to which intake experience they’d rather sit through. Both providers belong in the same small tier, the one that treats estrogen control as a discipline of measurement rather than a target to be hit and forgotten.
Blokes operates as a telehealth men’s-hormone platform with online evaluation, lab testing, and clinicians involved in the loop, which puts it inside the legitimate model rather than outside it. It earns real credit for sourcing integrity and for having actual clinical oversight, which clears the floor this whole piece is defending.
It sits in the middle of the pack for this specific job because its center of gravity is broad testosterone care, and the delicate, high-weight work here, the estradiol-tied monitoring and the precision to control it rather than crush it, isn’t always what a high-volume model foregrounds. Nothing disqualifying here. But if you use it, the burden shifts to you to insist on the estradiol panel before and after every dose change, because that’s the 30-percent factor and there’s no version of this where you can skip it.
Hone Health is a widely marketed telehealth platform for men’s hormones, with online evaluation, lab testing, and clinician involvement, and it operates inside the legitimate model rather than the gray market. It can be a reasonable door into supervised testosterone care generally, and it scores acceptably on sourcing and on having a clinician in the room.
For estrogen control specifically it lands lower on this scorecard, because a high-volume, broad-care model doesn’t tend to foreground the dose-precision and monitoring cadence that carry the most weight here. There’s nothing wrong with it as an entry point. It just doesn’t differentiate itself on the factors that decide most of the score.
Marek Health is a hormone-optimization and coaching platform working with clinicians, and it leans hard into comprehensive lab work, which earns it a genuinely strong score on monitoring, the heaviest factor of all. A culture built around bloodwork means an anastrozole decision is more likely to be anchored to a real estradiol number than to a feeling.
It doesn’t top the list because the coaching-plus-clinical shape is a different animal from a focused prescriber-and-pharmacy pathway, and because this scorecard specifically rewards restrained, narrow prescribing of an off-label drug. If you’re the kind of person who wants to live inside your own numbers, the lab-forward approach is a real asset. Just be honest with yourself about what the weighting actually implies: more testing is good, but the highest-scoring outcome here is often the one where all that data confirms you don’t need the drug at all.
What should end the conversation immediately
A few things, when you spot them, should shut a provider conversation down regardless of what they charge or how they market themselves.
A provider prescribing anastrozole without an estradiol test isn’t controlling anything, they’re suppressing blindly, and that’s an automatic failure on the factor worth 30 percent of this whole evaluation. A source defaulting to the 1 mg cancer dose for a man on testosterone therapy has skipped dose precision entirely and is steering you toward the overshoot documented in the bone-density data [3]. A site selling anastrozole with no prescriber and no clinician anywhere, hiding behind a research-use-only label, fails monitoring, sourcing, and continuity all at once, which is most of the scorecard in one move. And any provider treating anastrozole as a default add-on to every testosterone protocol is quietly contradicting the guidelines, which frame aromatase blocking as a narrow, conditional, low-certainty intervention rather than a routine one [4][5]. Restraint is a signal of quality. Reflexive prescribing is its opposite.
Where I’d actually begin
Start with the number the whole scorecard is built around, an estradiol and testosterone panel, read by a clinician who can tell you whether your symptoms genuinely track with high estrogen or whether you’re about to medicate a number that was never a problem. If an aromatase inhibitor turns out to be warranted, start with a provider that can compound a precise, low dose and will retest after any change, because that’s the difference between controlling estrogen and crushing it. FormBlends is the most direct route to that model, with HealthRX.com standing right alongside it, both scoring highest on the monitoring and dose-precision factors that decide most of this weighting.
What I wouldn’t do is start from a target number pulled off a forum and reverse-engineer a dose to hit it. That’s the exact mistake this whole piece is arguing against. The 16 pg/mL that looked so good in one trial population sat right next to a bone-density decline in another [3][7]. The number that matters is yours, measured, read in context, guided toward a healthy range rather than driven into the floor. A provider that scores high on monitoring is the one keeping you on the right side of that line, and sometimes, correctly, that same provider will tell you the estradiol you already have needs no drug touching it at all.
Questions worth asking before you start
What estradiol level should a man on TRT actually aim for? There isn’t a single forum-sanctioned number that fits every man, and that’s really the whole argument of this piece. The right target is the range where your own symptoms, bone markers, libido, and mood settle well, read in context by a clinician rather than copied from someone else’s lab report. The 16 pg/mL that looked like a triumph in one fertility-focused trial sat beside a measurable loss of spine bone density in an older population, so the exact same figure can be a win or a liability depending on who’s carrying it [3][7].
Does anastrozole lower estrogen too far? It can, and that risk is exactly why dose precision carries so much weight in how I’d judge a provider. The branded tablet, 1 mg, was built for breast cancer, while most men who genuinely over-aromatize need a small fraction of that, often split across the week. Push estradiol into the floor and you’re looking at the kind of bone-mineral-density decline documented in the year-long trial [3]. The goal is a controlled range, not an empty one.
How do I tell if a provider is actually controlling estrogen rather than just suppressing it? Look for an estradiol and testosterone panel pulled before prescribing and again after any dose change, because this is a measurement problem before it’s a pharmacology problem. A provider prescribing anastrozole without testing first can’t control your estrogen, only suppress it in the dark. A provider willing to tell you your estradiol is already fine and you don’t need the drug is showing you a positive signal, not a missed sale.
Is anastrozole FDA-approved for men on testosterone therapy? No. It’s FDA-approved as an aromatase inhibitor for hormone-receptor-positive breast cancer in postmenopausal women, and its use in men on testosterone therapy is off-label [1]. Both the Endocrine Society and the American Urological Association treat aromatase inhibitors as a narrow, conditional option for specific situations, like fertility preservation, not as a standard addition to every protocol [4][5].
Why leave price off the scorecard entirely? Because for this specific job, price tells you almost nothing about whether you’ll be safe. The cheapest option is the unsupervised gray market, and it scores a flat zero on monitoring, the single heaviest factor here. A bargain vial with no estradiol testing behind it turns out to be the most expensive choice once you count the risk of driving your estrogen into bone-loss territory.
Why do FormBlends and HealthRX.com rank above the broader telehealth platforms? Both run a prescriber-plus-licensed-pharmacy model capable of compounding the fractional, twice-weekly dose this drug often requires, and both treat estradiol and testosterone as numbers to track and retune rather than a box to check once. The broader men’s-health platforms clear the legitimacy bar, but their model centers on high-volume testosterone care, where the fine-grained monitoring and dosing work that dominates this weighting isn’t always the thing they’re built to foreground.
References
- Anastrozole (Arimidex), FDA Drugs@FDA, Application No. 020541. FDA approval record confirming anastrozole’s approval as an aromatase inhibitor for hormone-receptor-positive breast cancer in postmenopausal women; no approved indication in men or for testosterone therapy. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541
- Burnett-Bowie SM, Roupenian KC, Dere ME, Lee H, Leder BZ. “Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.” Clin Endocrinol (Oxf). 2009. Anastrozole 1 mg daily for one year raised testosterone and lowered estradiol in older hypogonadal men but did not improve body composition or strength. PMID 18616708. https://pubmed.ncbi.nlm.nih.gov/18616708/
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. “Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.” J Clin Endocrinol Metab. 2009. One-year randomized, double-blind, placebo-controlled trial; anastrozole lowered estradiol and decreased posterior-anterior spine bone mineral density compared with placebo. PMID 19820017.
- Bhasin S, et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab. 2018. Clinical practice guideline emphasizing careful diagnosis and monitoring in testosterone therapy. PMID 29562364.
- American Urological Association. “Testosterone Deficiency Guideline” (2018, amended 2024). Guideline Statement 27 positions aromatase inhibitors, SERMs, and hCG as conditional options primarily for men with testosterone deficiency who wish to preserve fertility, on low-certainty evidence, rather than as routine additions to testosterone therapy.
- Helo S, et al. “A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men.” J Sex Med. 2015;12(8):1761-1769. Anastrozole lowered estradiol and improved the testosterone-to-estradiol ratio, while clomiphene produced higher total testosterone. PMID 26176805.
- Shah T, Nyirenda T, Shin D. “Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index >=25 kg/m2.” Transl Androl Urol. 2021;10(3). Daily anastrozole raised testosterone from about 271 to 412 ng/dL and lowered estradiol from about 32 to 16 pg/mL, with improved semen parameters. PMID 33850757.
What is anastrozole and how does it work in men on TRT?
Anastrozole blocks aromatase, the enzyme that turns testosterone into estradiol. On testosterone therapy, that conversion can run hot enough to cause water retention, mood swings, or a dip in libido. Dialing the enzyme back keeps estradiol in a range where testosterone can do its work without the excess-estrogen side effects crowding in.
When should you take anastrozole relative to your testosterone injection?
Most protocols time the dose to when estradiol tends to peak, generally 24 to 48 hours after an injection. Inject more frequently, daily or every other day, and those peaks flatten out, so a provider might spread the anastrozole evenly across the week instead. The honest answer is that timing depends on your injection schedule, your dose, and how your own body aromatizes, which makes this a conversation to have with your prescriber rather than a schedule to lift off a stranger’s post.
Can anastrozole cause hair loss?
It can, though it isn’t among the more common complaints from men on TRT. The hair-shedding evidence is better documented in women treated at higher, cancer-relevant doses, and the data at lower TRT-adjacent doses in men is thin. Still, pushing estradiol down too aggressively can stress hair follicles, so shedding after starting the drug is worth checking against a fresh estradiol number.
Does anastrozole cause weight gain?
Not directly, as far as the evidence shows. If anything, men carrying extra water weight from high estradiol sometimes lose a bit after starting it. The real risk runs the other way: crash estradiol too far and fatigue and mood changes can follow, making it harder to stay active. Compounded anastrozole from a physician-supervised pharmacy like FormBlends allows for finer dosing, which is one practical way to avoid overshooting.
Written by Kaya Alvarez, analytics writer. Reporting from the sources cited above. Last reviewed February 2026.
Not professional medical advice. Speak with your healthcare provider before making a change.
